Antigen variation in a human glioblastoma: from the primary tumor to the second recurrence, permanent cell line and xenotransplantation tumors
- PMID: 2064311
Antigen variation in a human glioblastoma: from the primary tumor to the second recurrence, permanent cell line and xenotransplantation tumors
Abstract
Antigen expression in a human glioblastoma was investigated by immunochemical methods in the primary tumor, the first and second recurrence, a permanent cell line derived from the first recurrence and in its xenotransplantation tumors. In the primary tumor, GFAP, vimentin, S100, Leu-7 and glioma-associated antigens (GAA) as defined by the monoclonal antibodies (mAbs) MUC 2-39, MUC 8-22 and MUC 2-63 were markedly expressed. In the recurrences, gradual loss of GFAP and Leu-7 could be observed, whereas S100, vimentin and GAA gave similar results to those in the primary tumor. In contrast, fibronectin and collagen IV, which were restricted to the vessel walls in the primary tumor, were represented in sarcomatous areas of the recurrences. In some of these areas, co-expression of glial cell markers was observed. In short-term cell cultures, expression of glia- and glioma-associated antigens as well as fibronectin and collagen IV was comparable to that of the recurrent tumor tissue. In long-term passages, immunoreactivity of GFAP, Leu-7 and S100 decreased, whereas GAA, vimentin and fibronectin increased. Collagen IV positive cells were not visible beyond passage 15. Transplantation tumors were only partly positive for glial cell markers, but revealed strong immunoreactivity for GAA, fibronectin and collagen IV. With these observations we confirm that the phenotypic variability of glioma cells makes it difficult to identify the origin of cells in human glioblastomas from their antigenicity.
Similar articles
-
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.Cancer Res. 1983 Jun;43(6):2796-805. Cancer Res. 1983. PMID: 6342760
-
Establishment and characterization of a cell line from a human gliosarcoma.Cancer Res. 1986 Nov;46(11):5893-902. Cancer Res. 1986. PMID: 3019542
-
Identification of gliomas by morphological and immunocytochemical analysis in cell cultures.Ideggyogy Sz. 2002 May 20;55(5-6):173-9. Ideggyogy Sz. 2002. PMID: 12122877
-
Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system.Cancer. 1996 May 1;77(9):1884-91. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1884::AID-CNCR19>3.0.CO;2-W. Cancer. 1996. PMID: 8646689 Review.
-
Patterns of antigenic expression of human glioma cells.Crit Rev Neurobiol. 1991;6(2):119-47. Crit Rev Neurobiol. 1991. PMID: 1934088 Review.
Cited by
-
Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.PLoS One. 2015 May 21;10(5):e0124974. doi: 10.1371/journal.pone.0124974. eCollection 2015. PLoS One. 2015. PMID: 25996609 Free PMC article.
-
Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy.In Vitro Cell Dev Biol Anim. 2009 Oct;45(9):500-11. doi: 10.1007/s11626-009-9215-4. Epub 2009 Jun 16. In Vitro Cell Dev Biol Anim. 2009. PMID: 19533255
-
A comprehensive profile of recurrent glioblastoma.Oncogene. 2016 Nov 10;35(45):5819-5825. doi: 10.1038/onc.2016.85. Epub 2016 Apr 4. Oncogene. 2016. PMID: 27041580 Review.
-
Expression of annexin II in glioma cell lines and in brain tumor biopsies.J Neurooncol. 1998 May;38(1):11-8. doi: 10.1023/a:1005953000523. J Neurooncol. 1998. PMID: 9540053
-
Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas.J Neurooncol. 1995;24(3):267-80. doi: 10.1007/BF01052843. J Neurooncol. 1995. PMID: 7595757
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous